SEC Form 4 · accession 0001123292-16-002533
Zynerba Pharmaceuticals, Inc. · ZYNE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Warren D Cooper
Director
Period of report
May 25, 2016
Accepted (ET)
Jul 20, 2016 · 4:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001621443
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $7.90 | May 25, 2016 | A | 15,000 | A | — | May 25, 2026 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1The option vests on the earlier of (i) May 25, 2017 and (ii) the day before the 2017 annual meeting of stockholders of Zynerba Pharmaceuticals, Inc.